Kura Oncology Inc reports results for the quarter ended in September - Earnings Summary

Kura Oncology

02/11/2023 23:33

* Kura Oncology Inc  KURA.OQ  reported a quarterly adjusted
loss
of 50 cents​​ per share for the quarter ended in September,
higher than the same quarter last year, when the company
reported EPS of -53 cents.  The mean expectation of
thirteen analysts for the quarter was for a loss of 55 cents per
share. Wall Street expected results to range from -68 cents
to -50 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Kura Oncology Inc's reported EPS for the quarter was a
loss
of 50 cents​.
    * The company reported a quarterly loss of $38.6 million.
    * Kura Oncology Inc shares had fallen by 12.4% this
quarter and
lost 35.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Kura Oncology Inc
is $31.00 
This summary was machine generated from LSEG data November 2 at
11:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.55          -0.50          Beat
 Jun. 30 2023      -0.55          -0.53          Beat
 Mar. 31 2023      -0.54          -0.50          Beat
 Dec. 31 2022      -0.57          -0.49          Beat